Is insulin-like growth factor-1 involved in Parkinson’s disease development?

Publication date: Feb 11, 2020

Parkinson’s disease (PD) is a neurodegenerative disorder that results in the death of dopaminergic neurons within the substantia nigra pars compacta and the reduction in dopaminergic control over striatal output neurons, leading to a movement disorder most commonly characterized by akinesia or bradykinesia, rigidity and tremor. Also, PD is less frequently depicted by sensory symptoms (pain and tingling), hyposmia, sleep alterations, depression and anxiety, and abnormal executive and working memory related functions. On the other hand, insulin-like growth factor 1 (IGF-1) is an endocrine, paracrine and autocrine hormone with several functions including tissue growth and development, insulin-like activity, proliferation, pro-survival, anti-aging, antioxidant and neuroprotection, among others. Herein this review tries to summarize all experimental and clinical data to understand the pathophysiology and development of PD, as well as its clear association with IGF-1, supported by several lines of evidence: (1) IGF-1 decreases with age, while aging is the major risk for PD establishment and development; (2) numerous basic and translational data have appointed direct protective and homeostasis IGF-1 roles in all brain cells; (3) estrogens seem to confer women strong protection to PD via IGF-1; and (4) clinical correlations in PD cohorts have confirmed elevated IGF-1 levels at the onset of the disease, suggesting an ongoing compensatory or “fight-to-injury” mechanism.

Open Access PDF

, Castilla-Cort’azar, Aguirre, G.A., Femat-Rold’an, G., , Mart’in-Estal, and Espinosa, L. Is insulin-like growth factor-1 involved in Parkinson’s disease development? 23972. 2020 J Transl Med (18):1.

Concepts Keywords
Aging Injury
Akinesia PD neurodegenerative disorder
Antioxidant Pain
Anxiety Movement disorder
Autocrine Onset disease
Bradykinesia Hormones
Brain Branches of biology
Depression Endocrine system
Dopaminergic Growth factors
Endocrine Peptide hormones
Growth Factor Puberty
Homeostasis Endocrinology
Hormone IGF
Insulin Estrogen
Movement Disorder Insulin-like growth factor
Neurodegenerative Disorder
Working Memory


Type Source Name
disease MESH development
disease MESH neurodegenerative disorder
disease MESH death
disease MESH movement disorder
disease MESH bradykinesia
disease MESH tremor
disease MESH sleep
disease MESH depression
disease MESH anxiety
drug DRUGBANK Mecasermin
disease MESH aging
disease MESH estrogens
drug DRUGBANK Dopamine
pathway REACTOME Reproduction
disease MESH syndrome
disease MESH risk factors
disease MESH camptocormia
drug DRUGBANK Coenzyme M
drug DRUGBANK Dimercaprol
drug DRUGBANK gamma-Aminobutyric acid
drug DRUGBANK Isoxaflutole
pathway KEGG Lysosome
disease MESH Inflammation
pathway KEGG Apoptosis
disease MESH dementia
disease MESH Oxidative stress
disease MESH amyotrophic lateral sclerosis
drug DRUGBANK Oxygen
pathway KEGG Mitophagy
drug DRUGBANK Trihexyphenidyl
drug DRUGBANK Profenamine
pathway KEGG Autophagy
pathway KEGG Proteasome
disease MESH men
drug DRUGBANK Cholesterol
drug DRUGBANK Testosterone
drug DRUGBANK Methylergometrine
drug DRUGBANK Estradiol
drug DRUGBANK Inositol
drug DRUGBANK Curcumin
disease MESH lifestyle
drug DRUGBANK Caffeine
drug DRUGBANK Somatotropin
disease MESH liver cirrhosis
disease MESH intrauterine growth restriction
disease MESH metabolic syndrome
disease MESH demyelination
drug DRUGBANK L-Phenylalanine
drug DRUGBANK Erythropoietin
drug DRUGBANK Calcium
drug DRUGBANK Nitric Oxide
disease MESH multiple system atrophy
disease MESH progressive supranuclear palsy
disease MESH PSP
drug DRUGBANK Levodopa
disease MESH weight loss
drug DRUGBANK Leptin
drug DRUGBANK Lenomorelin
drug DRUGBANK Esomeprazole
disease MESH diabetes mellitus
drug DRUGBANK Sarizotan
disease MESH cancer
disease MESH edema
disease MESH Laron syndrome
disease MESH cirrhosis
disease MESH nutritional status
drug DRUGBANK Nitrogen
disease MESH osteopenia
disease MESH atrophy
drug DRUGBANK Dextrose unspecified form
disease MESH insulin resistance
pathway KEGG Insulin resistance
drug DRUGBANK Clonidine
drug DRUGBANK L-Arginine
drug DRUGBANK Somatorelin
drug DRUGBANK Serotonin
disease MESH cerebrovascular diseases
disease MESH Lewy body disease
disease MESH vascular dementia
disease MESH stroke
disease MESH central obesity
disease MESH obesity
disease MESH cardiovascular diseases
disease MESH dyskinesia
disease MESH pathology
drug DRUGBANK Iron
drug DRUGBANK Bean
drug DRUGBANK Guanosine
disease MESH fetus
drug DRUGBANK Manganese
disease MESH cognitive decline
disease MESH pituitary disorders
disease MESH shock
drug DRUGBANK Insulin-like growth factor II
drug DRUGBANK Nerve Growth Factor
drug DRUGBANK Potassium
drug DRUGBANK Activated charcoal
disease MESH pituitary dwarfism
disease MESH defects
disease MESH liver disease
drug DRUGBANK Amino acids
drug DRUGBANK Galactose
disease MESH hypogonadism

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *